SEC Form 4 · accession 0001104659-16-100655
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Hoberman
Officer — Chief Operating Officer
Period of report
Feb 24, 2016
Accepted (ET)
Feb 26, 2016 · 8:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 24, 2016 | A | 87,985 | $0.00 | A | 299,044 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $4.12 | Feb 24, 2016 | A | 176,234 | A | Feb 24, 2017 | Feb 24, 2026 | Common Stock | 176,234 | 176,234 | D |
Explanation of responses
- F1The 87,985 restricted shares will vest in four installments as follows: 21,997 shares on February 24, 2017; 21,996 shares on February 24, 2018; 21,996 shares on February 24, 2019; and 21,996 shares on February 24, 2020.
- F2The 176,234 options will vest in four installments as follows: 44,059 shares on February 24, 2017; 44,059 shares on February 24, 2018; 44,058 shares on February 24, 2019; and 44,058 shares on February 24, 2020.